Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children
To perform a cost-effectiveness analysis (CEA) between a standard antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 receptor antagonist-tropisetron (TROP)--in the control of acute emesis induced by highly emetogenic chemotherapy in children, considering tw...
| Main Authors: | , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Springer
2012
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/23753 |
| _version_ | 1793399906933669888 |
|---|---|
| author | Tejedor, I. (I.) Jimenez, M. (Miguel) Sierrasesumaga, L. (Luis) Giraldez, J. (J.) |
| author_facet | Tejedor, I. (I.) Jimenez, M. (Miguel) Sierrasesumaga, L. (Luis) Giraldez, J. (J.) |
| author_sort | Tejedor, I. (I.) |
| collection | DSpace |
| description | To perform a cost-effectiveness analysis (CEA) between a standard
antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 receptor
antagonist-tropisetron (TROP)--in the control of acute emesis induced by highly
emetogenic chemotherapy in children, considering two analytic perspectives:
hospital and patients. METHODS: The CEA was performed by constructing a decision
tree, for both analytic perspectives, of the possible outcomes of treatment with
TROP (single 0.2 mg/kg i.v.) or CPM (5-15 mg i.v. infusion for 3 doses) plus DEX
(2 mg/m2 i.v. bolus i.v. x2). The patients were stratified by age in two groups
(2-12 and 13-17). To estimate the probability of each endpoint at the decision
tree we have taken as a base a trial developed in the Department of Pediatrics.
Direct medical cost of primary therapy, failure, complications and side effects
were included in the cost calculations. RESULTS: From patients' analytic
perspective, TROP was more cost-effective than CPM-DEX for both groups of
patients. Discrepancy between both analytic perspectives in 13-17 year-old
patient's group was resolved in favour of the option chosen from the patients'
analytic perspective (TROP). Sensitivity analysis showed the reliability of the
results. CONCLUSIONS: 1. TROP was more cost-effective than CPM-DEX. 2. Taking
into account the patients' analytic perspective is essential when we compare
antiemetics pharmacoeconomically. 3. It seems necessary to increase the
effectiveness of TROP in pediatric patients receiving highly emetogenic
chemotherapy with strategies such as the addition of a steroid. |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-23753 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2012 |
| publisher | Springer |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-237532020-03-03T20:29:44Z Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children Tejedor, I. (I.) Jimenez, M. (Miguel) Sierrasesumaga, L. (Luis) Giraldez, J. (J.) Antiemetics/adverse effects/economics/therapeutic use Dexamethasone/adverse effects/economics/therapeutic use Vomiting/chemically induced/prevention & control To perform a cost-effectiveness analysis (CEA) between a standard antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 receptor antagonist-tropisetron (TROP)--in the control of acute emesis induced by highly emetogenic chemotherapy in children, considering two analytic perspectives: hospital and patients. METHODS: The CEA was performed by constructing a decision tree, for both analytic perspectives, of the possible outcomes of treatment with TROP (single 0.2 mg/kg i.v.) or CPM (5-15 mg i.v. infusion for 3 doses) plus DEX (2 mg/m2 i.v. bolus i.v. x2). The patients were stratified by age in two groups (2-12 and 13-17). To estimate the probability of each endpoint at the decision tree we have taken as a base a trial developed in the Department of Pediatrics. Direct medical cost of primary therapy, failure, complications and side effects were included in the cost calculations. RESULTS: From patients' analytic perspective, TROP was more cost-effective than CPM-DEX for both groups of patients. Discrepancy between both analytic perspectives in 13-17 year-old patient's group was resolved in favour of the option chosen from the patients' analytic perspective (TROP). Sensitivity analysis showed the reliability of the results. CONCLUSIONS: 1. TROP was more cost-effective than CPM-DEX. 2. Taking into account the patients' analytic perspective is essential when we compare antiemetics pharmacoeconomically. 3. It seems necessary to increase the effectiveness of TROP in pediatric patients receiving highly emetogenic chemotherapy with strategies such as the addition of a steroid. 2012-11-21T12:18:09Z 2012-11-21T12:18:09Z 1999 info:eu-repo/semantics/article https://hdl.handle.net/10171/23753 eng http://link.springer.com/article/10.1023%2FA%3A1008693706516?LI=true#page-1 info:eu-repo/semantics/openAccess application/pdf Springer |
| spellingShingle | Antiemetics/adverse effects/economics/therapeutic use Dexamethasone/adverse effects/economics/therapeutic use Vomiting/chemically induced/prevention & control Tejedor, I. (I.) Jimenez, M. (Miguel) Sierrasesumaga, L. (Luis) Giraldez, J. (J.) Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| title | Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| title_full | Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| title_fullStr | Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| title_full_unstemmed | Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| title_short | Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| title_sort | cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children |
| topic | Antiemetics/adverse effects/economics/therapeutic use Dexamethasone/adverse effects/economics/therapeutic use Vomiting/chemically induced/prevention & control |
| url | https://hdl.handle.net/10171/23753 |
| work_keys_str_mv | AT tejedorii costeffectivenessanalysisoftropisetronvschlorpromazinedexamethasoneinthecontrolofacuteemesisinducedbyhighlyemetogenicchemotherapyinchildren AT jimenezmmiguel costeffectivenessanalysisoftropisetronvschlorpromazinedexamethasoneinthecontrolofacuteemesisinducedbyhighlyemetogenicchemotherapyinchildren AT sierrasesumagalluis costeffectivenessanalysisoftropisetronvschlorpromazinedexamethasoneinthecontrolofacuteemesisinducedbyhighlyemetogenicchemotherapyinchildren AT giraldezjj costeffectivenessanalysisoftropisetronvschlorpromazinedexamethasoneinthecontrolofacuteemesisinducedbyhighlyemetogenicchemotherapyinchildren |